PREVALENCE OF PHENOTYPIC ACTIVATED PROTEIN-C RESISTANCE (APCR) IN VENOUS THROMBOEMBOLIC PATIENTS

Until the discovery of activated protein C resistance (APCR),(1) less than 10% of patients with venous thromboembolism (VT) showed defects i n proteins involved in the inhibition of coagulation. APCR is caused b y a single point mutation in the factor V gene,(2) and it is accepted that APCR is associated with an increased risk for VT.(3,4) In this wo rk, we studied the prevalence of APCR in venous thromboembolic patient s and found it to be 10.5% compared with 4.5% in controls (p = 0.105).